A Phase 2, Randomized, Double-blind, Dose Response Study of Oral Testosterone in Subjects With Hypogonadism
Latest Information Update: 09 May 2019
Price :
$35 *
At a glance
- Drugs Testosterone (Primary)
- Indications Hypogonadism
- Focus Pharmacokinetics
- Sponsors TesoRx
- 14 Dec 2015 No of arms changed from 2 to 10 as per ClinicalTrials.gov record.
- 30 Jun 2014 Status changed from recruiting to completed according to the ClinicalTrials.gov record.
- 16 May 2014 According to a TesoRx media release, the results of this trial are expected in June 2014.